Scholar Rock HoldingSRRK
Recorded

Scholar Rock Holding 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 8 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen, and welcome to Scholar Rock's third quarter 2026 conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. To ask a question during this session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. This call is being recorded on Tuesday, November 10th, 2026. I would now like to turn the conference over to Scholar Rock. Please go ahead. Good morning.

Laura EkasVP of Investor Relations

I am Laura Ekas, Vice President, Investor Relations at Scholar Rock. With me today are David Hallal, Chairman and Chief Executive Officer, Keith Woods, Chief Operating Officer, Akshay Vaishnaw, President of R&D, and Vikas Sinha, Chief Financial Officer. During today's call, David will provide introductory remarks and a business overview. Keith will discuss the U.S. launch of ISEMBYLD and global commercial readiness. Akshay will review our regulatory and R&D progress, and Vikas will provide a financial update. We will then open the call for questions. Before we begin, I'd like to remind you that during this call, we will be making various statements about Scholar Rock's expectations, plans, and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Laura EkasVP of Investor Relations

Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date. I encourage you to go to the Investors and Media section of our website for our most up-to-date SEC statements and filings. With that, I'd like to turn the call over to David. David? Thank you, Laura, and good morning.

David HallalChairman and CEO

Thanks to everyone for joining our third quarter earnings call. Today, Scholar Rock is operating from a position of great strength, and we are executing with focus, discipline, and urgency. In mid-September, we received FDA approval well ahead of our PDUFA date for ISEMBYLD, the world's first and only muscle-targeted therapy for children and adults living with SMA. Following approval, we immediately commenced our U.S. launch. In early October, we resubmitted our apitegromab MAA in Europe for the treatment of children and adults with SMA. The application, which now includes our alternate fill-finish facility, has been validated, and we expect a CHMP opinion in the first half of 2027. In early November, we submitted our apitegromab JNDA in Japan, two months ahead of our guidance.

David HallalChairman and CEO

The application was accepted under priority review, and pending approval, we anticipate a launch in Japan near year-end 2027. In Q3, we also commenced dosing in our phase II FORGE study evaluating apitegromab in people living with FSHD. Finally, this morning, we announced we have entered into a definitive agreement to monetize our priority review voucher for $205 million, which will further strengthen our financial position to fund our ambitious global commercial and R&D growth initiatives. With this, let me turn to our U.S. approval and launch of ISEMBYLD. ISEMBYLD is a highly innovative myostatin inhibitor and the world's first and only muscle-targeted therapy approved for patients with SMA. Over the past decade, while SMN-targeted therapies have brought needed innovation to the SMA community by improving motor neuron health, significant unmet need remains. Muscle is the principal organ clinically affected by SMA and has been unaddressed.

David HallalChairman and CEO

To underscore this point, gaining muscle strength was the number one need amongst SMA patients in a 2026 Cure SMA survey. In addition, more than three-quarters of neurologists recognize that the future of treatment for patients with SMA is an approach that targets both the motor neuron and the muscle. Now, with ISEMBYLD, Scholar Rock is ushering in the next phase of needed innovation for the SMA community. Importantly, the FDA-approved label provides a substantial opportunity to serve patients. ISEMBYLD is indicated for all patients with SMA 2 years of age and older who are receiving an SMN2-targeted treatment. Our U.S. label is underpinned by the compelling clinical benefits ISEMBYLD can bring to children and adults with SMA.

David HallalChairman and CEO

For patients receiving an SMN2-targeted treatment in our global, randomized, double-blind, placebo-controlled phase III SAPPHIRE study, ISEMBYLD changed the progression of SMA from a loss of motor function to a gain of motor function. At the recommended dose, ISEMBYLD delivered a robust, clinically meaningful 2.2-point improvement in motor function compared with patients receiving an SMN2-targeted therapy alone, as measured by the gold standard Hammersmith Functional Motor Scale-Expanded. With this strong foundation in place, our experienced Scholar Rock commercial team is now doing what we know well and what we do well. Launching a highly innovative first-in-class rare disease therapy with the potential to dramatically improve the lives of patients. Immediately following the approval of ISEMBYLD, our team swiftly and successfully executed initial launch activities, and we are very pleased with our progress in these earliest weeks.

David HallalChairman and CEO

Our launch metrics reinforce our expectations and confidence in our opportunity to serve the estimated 6,600 patients with SMA in the U.S. who are currently receiving an SMN2 targeted therapy. Shortly, Keith will discuss four strategic imperatives with regards to our early U.S. launch dynamics: awareness, education, demand, and access. I'd like to take a few moments now to touch upon demand and access. In terms of demand for ISEMBYLD through the end of October, we are seeing a strong number of patients enrolling in Scholar Rock Supports. In these early weeks since approval, we are very encouraged by the broad-based demand as reflected by both the consistent volume of patients enrolling into the program and by the wide range of prescribers and patients. In the first six weeks of launch, enrollments are balanced across all geographies nationwide.

David HallalChairman and CEO

More than one-third of the top 140 SMA treatment centers have enrolled initial patients, and a significant number of enrollments are coming from centers outside of the top 140. The mix of patients enrolling in Scholar Rock Supports is just as diverse. Importantly, ISEMBYLD treatment-naive patients outnumber those who are starting the transition from our clinical trials and EAP program. Children are the largest enrolled group of patients, but a substantial number of adults have also enrolled. Patients reflect the full range of disease trajectories, including improving, plateaued, and declining motor function. Consistent with SMN2 prescribing patterns, patients are balanced across EVRYSDI, SPINRAZA, and HD SPINRAZA background therapy, including some who had previously received ZOLGENSMA.

David HallalChairman and CEO

Thus far, the pace of demand as measured by patients enrolling in Scholar Rock Supports has been very steady and consistent on a weekly basis, and we expect this trend to continue as we aim to serve an increasing number of new patients over time. As we expected, strong demand is outpacing reimbursement and access at this stage. While I am very encouraged by early patient-by-patient approvals across insurance types and sites of care, initial delays and denials are common for any first-in-class rare disease launch. Given the timing of when patient enrollments have been received, combined with the anticipated 60 to 90 days or longer from prescription to infusion in this very early stage of launch, we anticipate the majority of the patients who enrolled through October will begin infusions in 2027.

David HallalChairman and CEO

We expect steady progress on payer approvals over time and remain confident that it is a matter of when and not if eligible SMA patients will receive ISEMBYLD therapy. We are building an access engine that will ultimately support broad and reliable access to ISEMBYLD. Our initial performance across these early indicators reinforce our expectations and confidence in our opportunity to serve a steady and consistent number of new patients for quarters and years to come. Keith will share much more detail on our early U.S. launch progress in just a few moments. Turning now to our global regulatory and pipeline priorities. We are very pleased with the meaningful progress we've made in recent weeks towards serving children and adults living with SMA in both Europe and Japan. Akshay will discuss these important regulatory advancements and progress across our world-leading anti-myostatin pipeline later in the call.

David HallalChairman and CEO

Finally, turning to the financials. We reported $0.6 million in ISEMBYLD revenue in the third quarter, reflecting initial inventory shipped to our specialty network. We ended the quarter with $413.6 million in cash equivalents, and marketable securities. Now, with the sale of our priority review voucher that will bring in an additional $205 million, Scholar Rock has the financial strength and flexibility to support our key priorities without the need for an equity offering at this time. In closing, we have never been better positioned to deliver on the opportunity ahead as we work with urgency to improve the lives of patients living with SMA and other rare and severe neuromuscular diseases. With that, I'll turn the call over to Keith to discuss the U.S. launch of ISEMBYLD and our apitegromab commercial readiness globally. Keith? Thanks, David, and good morning, everyone.

Keith WoodsCOO

Isembly's position to define a new standard of care for the estimated 6,600 patients living with SMA in the U.S. who are receiving an SMN2 targeted therapy. As I've shared previously, the vast majority of patients continue to experience persistent and progressive muscle atrophy that limits both function and independence despite receiving an SMN targeted treatment. Now, with the FDA approval of ISEMBYLD, we are ushering in the next phase of needed innovation with this first-ever muscle-targeted therapy. In the 13 business days between the approval of ISEMBYLD on Friday, September 11, and the end of the third quarter, we executed flawlessly on our key priorities. Immediately following approval, Scholar Rock Supports began working with physicians and families to conduct insurance verifications for initial patients.

Keith WoodsCOO

Within one week of approval, ISEMBYLD vials were labeled, packaged, and shipped to our specialty network, and we filed the J-code application, which will give us an ISEMBYLD-specific J-code on April 1, which is the shortest timeline possible. We are very pleased with the progress in these earliest weeks. Our launch metrics reinforce our expectations and confidence in our opportunity to serve the broad SMA community. Let me now provide some important additional detail on our launch as it relates to awareness, education, demand, and access. Patient and caregiver awareness and engagement is meeting our high expectations. For example, in the days immediately following approval, we had nearly 1,000 patients and caregivers register for ISEMBYLD educational webinars hosted by Cure SMA and MDA.

Keith WoodsCOO

Through our efforts with our Life Takes Muscle campaign, we had more than 10,000 opt-ins from patients, caregivers, and HCPs to receive notification of the ISEMBYLD approval. In terms of prescriber education, following the ISEMBYLD approval, our highly experienced U.S. team began engaging with the SMA treatment centers, their physicians, and care teams on the compelling clinical benefits of ISEMBYLD. Reach to the SMA treatment centers is already deep and wide. Through the end of October, so in just the first six weeks of our launch, our team has engaged with 95% of the top 140 SMA treatment centers. This is a tremendous achievement, given that in my experience, it would typically take at least four months to reach this proportion of your target audience. In terms of demand, as David said, we are seeing consistent volume and breadth of prescribers and patients.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day